Table 1 Characteristics of trials of LC for CKD-MBD in dialysis patients
Study | Intervention | No. of patients | Duration (Week) | Dialysis methods | |
|---|---|---|---|---|---|
LC group | Control group | ||||
Fouad Al-Baaj 2005 | LC 375-2250 mg/d | Placebo | 36 | 4 | HD |
Melanie S. Joy 2003 | LC 375 mg, 750 mg, 1500 mg, 2250 mg, 3000 mg/day | Placebo | 93 | 4 | HD and CAPD |
Finn WF 2006 | LC<3000 mg/d (serum phosphate ≤5.9 mg/dl) | pre-study phosphate binder (serum phosphate ≤5.9 mg/dl) | 1359 | 104 | HD |
Patrick. C 2003 | LC<3750 mg/d | CC<9000 mg/d | 98 | 52 | HD |
N. D TOUSSAINT 2011 | LC (serum phosphate in the normal range) | CC (serum phosphate in the normal range) | 45 | 72 | HD and CAPD |
T.shigematsu 2008 | LC+CC-liked placebo 750, 1500, 2250 mg/d (serum phosphate at 3.5-5.5 mg/dl) | CC+LC-liked placebo 1500, 3000, 4500 mg/d(serum phosphate 3.5-5.5 mg/dl) | 258 | 8 | HD |
H H Mallache 2008 | LC<3000mg/d (serum phosphate≤5.9mg/dl) | Previous phosphate binder (serum phosphate ≤5.9 mg/dl) | 65 | 52 | HD |
T.shigematsu 2007 | LC 750 mg, 1500 mg, 2250 mg, 3000 mg/day | Placebo | 142 | 6 | HD |
Spasovski GB 2006 | LC<3000 mg/d (serum phosphate <1.8 mmol/L) | CC< 4000 mg/d (serum phosphate <1.8 mmol/L) | 24 | 52 | Not describe |
A.J. Hutchison 2005 | LC 250-3000 mg/d | CC 1000-9000 mg/d | 767 | 25 | HD |
S.-S. Chiang 2005 | LC 375-3000 mg/d (can’t change during study) | Placebo | 61 | 4 | HD |
Finn WF 2004 | LC 225 mg, 675 mg, 1350 mg, 2250 mg/day | Placebo | 144 | 6 | HD |
Yong Kyu Lee 2013 | LC 1500 mg at start, regulate to control the serum phosphate at 3.5-5.5 mg/dl | CC 3000 mg at start, regulate to control the serum phosphate at 3.5-5.5 mg/dl | 50 | 24 | CAPD |
Xu 2013 | LC 1500 mg-3000 mg/day | Placebo | 230 | 4 | HD and CAPD |
Sprague S.M 2009 | LC 3,000 mg/day | SH 6,400 mg/day | 333 | 4 | HD |
Kasai S 2012 | LC 375–2250 mg/day | SH 750–9000 mg/day | 84 | 13 | HD |